-
Posted by
Two Blokes Jun 13 -
Filed in
Stock
-
6 views
Crispr Therapeutics AG is transitioning to a commercial company, with CASGEVY's rollout and a robust pipeline in cardiovascular, autoimmune, and oncology driving long-term potential. The cardiovascular franchise, especially CTX-310 and CTX-320, offers blockbuster potential with best-in-class efficacy and a compelling one-time treatment value proposition. Recent partnerships, like Sirius Therapeutics, expand Crispr's multi-modal platform and open new multi-billion dollar market opportunities in siRNA and beyond.
